Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Journal of Hypertension

Volumn 22, Issue 9, 2004, Pages 1805-1811

  Ibsen, Hans ^a   Wachtell, Kristian ^a,b   Olsen, Michael H ^a   Borch Johnsen, Knut ^c   Lindholm, Lars H ^d   Mogensen, Carl Erik ^e   Dahlöf, Björn ^f   Devereux, Richard B ^b   De Faire, Ulf ^g   Fyhrquist, Frej ^h   Julius, Stevo ⁱ   Kjeldsen, Sverre E ^j   Lederballe Pedersen, Ole ^k   Nieminen, Markku S ^h   Omvik, Per ^l   Oparil, Suzanne ^m   Wan, Ying ⁿ  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c STENO DIABETES CENTER   (Denmark)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^k VIBORG HOSPITAL   (Denmark)

^l HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Albuminuria; Atenolol; Hypertension; Left ventricular hypertrophy; LIFE study; Losartan; Morbidity and mortality; Stroke

Indexed keywords

ALBUMIN; ATENOLOL; CALCIUM ANTAGONIST; CREATININE; DIURETIC AGENT; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR SYSTEM; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 4344716513     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200409000-00026     Document Type: Article

References (19)

1. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20:353-355.
2. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Sohroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35:898-903.
3. Bigazzi R, Bianchi S, Campese VM, Baldari G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension [published erratum, Nephron 1992; 82:120]. Nephron 1992; 61:94-97.
4. Wachtell K, Ibsen H, Oben MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Ann Intern Med 2003; 139:901-906.
5. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20:405-412.
6. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
7. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143:319-326.
8. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci Colch 1995; 88:629-633.
9. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001; 103:1869-1874.
10. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
11. Chen C, Wang HW, Snapinn S. Proportion of treatment effect (PTE) explained by a surrogate marker. Stat Med 2003; 22:3449-3459.
12. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) study. Circulation 2003; 108:684-690.
13. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
14. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, de Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65:1041-1049.
15. Schiffrin EL. Effect of antihypertensive treatment on small artery remodeling in hypertension. Can J Physiol Pharmacol 2003; 81:168-176.
16. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678.
17. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
18. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41:1063-1071.
19. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39:794-798.